| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 317 | 2024 | 2278 | 40.350 |
Why?
|
| Esophageal Neoplasms | 339 | 2024 | 3168 | 37.010 |
Why?
|
| Adenocarcinoma | 340 | 2024 | 7789 | 24.290 |
Why?
|
| Esophagogastric Junction | 94 | 2023 | 543 | 17.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 197 | 2024 | 15862 | 7.470 |
Why?
|
| Chemoradiotherapy | 68 | 2022 | 1946 | 7.320 |
Why?
|
| Gastrectomy | 52 | 2024 | 451 | 6.580 |
Why?
|
| Esophagectomy | 72 | 2022 | 911 | 6.180 |
Why?
|
| Fluorouracil | 122 | 2022 | 1944 | 6.070 |
Why?
|
| Peritoneal Neoplasms | 25 | 2024 | 821 | 5.870 |
Why?
|
| Carcinoma, Squamous Cell | 87 | 2023 | 5437 | 5.580 |
Why?
|
| Combined Modality Therapy | 157 | 2024 | 8865 | 4.480 |
Why?
|
| Neoadjuvant Therapy | 85 | 2022 | 4975 | 4.450 |
Why?
|
| Chemoradiotherapy, Adjuvant | 30 | 2021 | 565 | 4.130 |
Why?
|
| Humans | 764 | 2024 | 261506 | 3.810 |
Why?
|
| Neoplasm Staging | 149 | 2023 | 13658 | 3.700 |
Why?
|
| Chemotherapy, Adjuvant | 75 | 2021 | 3890 | 3.490 |
Why?
|
| Anus Neoplasms | 23 | 2022 | 411 | 3.400 |
Why?
|
| Cisplatin | 85 | 2022 | 2432 | 3.310 |
Why?
|
| Antineoplastic Agents | 105 | 2024 | 14289 | 3.220 |
Why?
|
| Tegafur | 20 | 2017 | 50 | 3.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 14 | 2020 | 1439 | 3.160 |
Why?
|
| Prognosis | 160 | 2023 | 21713 | 3.090 |
Why?
|
| Middle Aged | 397 | 2023 | 86204 | 3.030 |
Why?
|
| Aged | 349 | 2023 | 70117 | 2.970 |
Why?
|
| Oxonic Acid | 15 | 2017 | 24 | 2.870 |
Why?
|
| Taxoids | 28 | 2020 | 967 | 2.830 |
Why?
|
| Male | 445 | 2024 | 123000 | 2.820 |
Why?
|
| Biomarkers, Tumor | 51 | 2023 | 10331 | 2.820 |
Why?
|
| Gastrointestinal Neoplasms | 20 | 2020 | 600 | 2.720 |
Why?
|
| Receptor, ErbB-2 | 19 | 2023 | 2518 | 2.700 |
Why?
|
| Camptothecin | 19 | 2023 | 517 | 2.670 |
Why?
|
| Antineoplastic Agents, Phytogenic | 21 | 2021 | 852 | 2.670 |
Why?
|
| Female | 440 | 2023 | 141928 | 2.580 |
Why?
|
| Paclitaxel | 41 | 2023 | 1996 | 2.570 |
Why?
|
| Survival Rate | 121 | 2024 | 12221 | 2.560 |
Why?
|
| Carcinoma, Signet Ring Cell | 11 | 2022 | 170 | 2.490 |
Why?
|
| Adult | 292 | 2022 | 77950 | 2.420 |
Why?
|
| B7-H1 Antigen | 14 | 2023 | 1022 | 2.300 |
Why?
|
| Aged, 80 and over | 142 | 2022 | 29902 | 2.240 |
Why?
|
| Neoplastic Stem Cells | 13 | 2021 | 1443 | 2.210 |
Why?
|
| Neoplasm Recurrence, Local | 59 | 2023 | 10035 | 2.100 |
Why?
|
| Positron-Emission Tomography | 23 | 2015 | 2173 | 2.060 |
Why?
|
| Carcinoma | 28 | 2024 | 2578 | 2.000 |
Why?
|
| Survival Analysis | 82 | 2022 | 9180 | 1.940 |
Why?
|
| Preoperative Care | 39 | 2021 | 1529 | 1.920 |
Why?
|
| Treatment Outcome | 135 | 2022 | 32848 | 1.890 |
Why?
|
| SOX9 Transcription Factor | 7 | 2022 | 170 | 1.880 |
Why?
|
| Antibodies, Monoclonal | 20 | 2024 | 4367 | 1.830 |
Why?
|
| Molecular Targeted Therapy | 17 | 2019 | 2330 | 1.810 |
Why?
|
| Hyperthermia, Induced | 6 | 2024 | 510 | 1.800 |
Why?
|
| Lymph Node Excision | 17 | 2021 | 1959 | 1.770 |
Why?
|
| Retrospective Studies | 146 | 2023 | 37905 | 1.750 |
Why?
|
| Transcription Factors | 21 | 2023 | 5270 | 1.720 |
Why?
|
| Neoplasm Metastasis | 38 | 2021 | 5112 | 1.710 |
Why?
|
| Barrett Esophagus | 16 | 2018 | 569 | 1.710 |
Why?
|
| Lymph Nodes | 22 | 2021 | 2967 | 1.700 |
Why?
|
| Esophagus | 11 | 2018 | 553 | 1.680 |
Why?
|
| Lymphatic Metastasis | 47 | 2021 | 4844 | 1.670 |
Why?
|
| Antimetabolites, Antineoplastic | 15 | 2020 | 1299 | 1.670 |
Why?
|
| Disease-Free Survival | 65 | 2022 | 10001 | 1.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 29 | 2024 | 3251 | 1.630 |
Why?
|
| Induction Chemotherapy | 7 | 2020 | 669 | 1.560 |
Why?
|
| Salvage Therapy | 15 | 2021 | 2054 | 1.550 |
Why?
|
| Radiotherapy, Adjuvant | 37 | 2017 | 2231 | 1.480 |
Why?
|
| Clinical Trials, Phase III as Topic | 19 | 2022 | 447 | 1.420 |
Why?
|
| Drug Resistance, Neoplasm | 27 | 2021 | 5178 | 1.400 |
Why?
|
| Follow-Up Studies | 63 | 2022 | 14889 | 1.400 |
Why?
|
| Neoplasms | 39 | 2024 | 15193 | 1.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2021 | 833 | 1.360 |
Why?
|
| Laparoscopy | 14 | 2020 | 1225 | 1.350 |
Why?
|
| Proportional Hazards Models | 39 | 2022 | 4988 | 1.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 34 | 2022 | 8873 | 1.320 |
Why?
|
| Hedgehog Proteins | 7 | 2019 | 424 | 1.320 |
Why?
|
| Gene Expression Profiling | 18 | 2021 | 5159 | 1.310 |
Why?
|
| Carcinoid Tumor | 10 | 2008 | 280 | 1.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 13 | 2024 | 1533 | 1.240 |
Why?
|
| Kaplan-Meier Estimate | 39 | 2021 | 6207 | 1.240 |
Why?
|
| Clinical Trials as Topic | 37 | 2020 | 3719 | 1.230 |
Why?
|
| Neovascularization, Pathologic | 7 | 2019 | 1547 | 1.220 |
Why?
|
| Phosphoproteins | 7 | 2017 | 1152 | 1.220 |
Why?
|
| Microsatellite Instability | 6 | 2022 | 400 | 1.200 |
Why?
|
| Medical Oncology | 13 | 2022 | 1423 | 1.180 |
Why?
|
| Cell Line, Tumor | 37 | 2024 | 14551 | 1.140 |
Why?
|
| Radiation Tolerance | 9 | 2020 | 629 | 1.140 |
Why?
|
| Bridged-Ring Compounds | 5 | 2020 | 183 | 1.140 |
Why?
|
| Esophagoscopy | 12 | 2015 | 291 | 1.120 |
Why?
|
| Signal Transduction | 26 | 2021 | 11965 | 1.120 |
Why?
|
| Colorectal Neoplasms | 26 | 2021 | 3578 | 1.090 |
Why?
|
| Immunotherapy | 17 | 2024 | 3341 | 1.080 |
Why?
|
| Mitomycin | 14 | 2020 | 208 | 1.070 |
Why?
|
| Fluorodeoxyglucose F18 | 12 | 2020 | 1226 | 1.070 |
Why?
|
| Drug Combinations | 17 | 2017 | 621 | 1.020 |
Why?
|
| NF-kappa B | 8 | 2017 | 1549 | 1.020 |
Why?
|
| Endosonography | 14 | 2017 | 536 | 1.020 |
Why?
|
| Platinum Compounds | 5 | 2020 | 131 | 1.010 |
Why?
|
| Clinical Decision-Making | 3 | 2016 | 524 | 1.000 |
Why?
|
| Rectal Neoplasms | 23 | 2021 | 1202 | 0.990 |
Why?
|
| Tumor Microenvironment | 14 | 2024 | 2864 | 0.980 |
Why?
|
| Drug Administration Schedule | 44 | 2015 | 3472 | 0.970 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 489 | 0.960 |
Why?
|
| RNA, Long Noncoding | 5 | 2021 | 598 | 0.950 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 5 | 2020 | 169 | 0.940 |
Why?
|
| Nomograms | 4 | 2016 | 313 | 0.940 |
Why?
|
| Liver Neoplasms | 22 | 2018 | 4557 | 0.930 |
Why?
|
| Organoplatinum Compounds | 12 | 2018 | 702 | 0.920 |
Why?
|
| Galectin 3 | 3 | 2023 | 138 | 0.920 |
Why?
|
| Remission Induction | 24 | 2017 | 3569 | 0.900 |
Why?
|
| Trastuzumab | 9 | 2023 | 696 | 0.870 |
Why?
|
| ErbB Receptors | 9 | 2016 | 2295 | 0.870 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1350 | 0.860 |
Why?
|
| Cell Proliferation | 19 | 2022 | 7226 | 0.860 |
Why?
|
| Quality of Life | 19 | 2024 | 4532 | 0.850 |
Why?
|
| Disease Progression | 32 | 2023 | 6682 | 0.840 |
Why?
|
| Cell Cycle Proteins | 5 | 2023 | 2045 | 0.840 |
Why?
|
| Prospective Studies | 32 | 2022 | 12873 | 0.840 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2019 | 355 | 0.840 |
Why?
|
| Azepines | 2 | 2020 | 124 | 0.840 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2019 | 1248 | 0.830 |
Why?
|
| Gene Knockout Techniques | 2 | 2020 | 276 | 0.830 |
Why?
|
| Tumor Burden | 8 | 2020 | 1987 | 0.830 |
Why?
|
| Leucovorin | 10 | 2021 | 332 | 0.790 |
Why?
|
| Gossypol | 1 | 2021 | 28 | 0.770 |
Why?
|
| Pyrimidines | 4 | 2020 | 3518 | 0.760 |
Why?
|
| Liquid Biopsy | 2 | 2019 | 158 | 0.760 |
Why?
|
| DNA-Binding Proteins | 13 | 2023 | 4821 | 0.760 |
Why?
|
| Pancreatic Neoplasms | 26 | 2023 | 5061 | 0.750 |
Why?
|
| Pyridines | 8 | 2009 | 1244 | 0.750 |
Why?
|
| Glycolysis | 2 | 2020 | 519 | 0.750 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2020 | 26 | 0.750 |
Why?
|
| Immunohistochemistry | 26 | 2023 | 7548 | 0.740 |
Why?
|
| Radiotherapy, Intensity-Modulated | 14 | 2022 | 2104 | 0.740 |
Why?
|
| Stomach | 5 | 2024 | 387 | 0.740 |
Why?
|
| Infusions, Intravenous | 21 | 2017 | 1382 | 0.730 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2021 | 1546 | 0.730 |
Why?
|
| Animals | 61 | 2024 | 59536 | 0.720 |
Why?
|
| Polymorphism, Genetic | 7 | 2019 | 1450 | 0.720 |
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2022 | 2594 | 0.720 |
Why?
|
| Zinc Finger Protein GLI1 | 3 | 2017 | 111 | 0.700 |
Why?
|
| Karyotyping | 2 | 2021 | 1022 | 0.700 |
Why?
|
| PPAR delta | 1 | 2019 | 55 | 0.690 |
Why?
|
| Etoposide | 15 | 2000 | 870 | 0.680 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.660 |
Why?
|
| MicroRNAs | 13 | 2020 | 2947 | 0.660 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2016 | 272 | 0.650 |
Why?
|
| Triazoles | 2 | 2020 | 617 | 0.650 |
Why?
|
| Genetic Engineering | 1 | 2020 | 288 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 129 | 0.630 |
Why?
|
| Ascites | 3 | 2024 | 198 | 0.620 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 383 | 0.610 |
Why?
|
| Cohort Studies | 20 | 2021 | 9244 | 0.610 |
Why?
|
| Postoperative Complications | 17 | 2020 | 5542 | 0.610 |
Why?
|
| Mice | 32 | 2024 | 34495 | 0.610 |
Why?
|
| Treatment Failure | 15 | 2016 | 1391 | 0.610 |
Why?
|
| Neoplasm, Residual | 11 | 2016 | 1656 | 0.610 |
Why?
|
| Radiotherapy Dosage | 26 | 2019 | 3842 | 0.600 |
Why?
|
| Radiotherapy | 20 | 2013 | 1824 | 0.600 |
Why?
|
| Texas | 19 | 2021 | 6311 | 0.600 |
Why?
|
| Retinal Dehydrogenase | 2 | 2015 | 91 | 0.590 |
Why?
|
| Colostomy | 4 | 2013 | 70 | 0.590 |
Why?
|
| Early Detection of Cancer | 5 | 2017 | 1258 | 0.590 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 441 | 0.580 |
Why?
|
| Ipilimumab | 5 | 2023 | 710 | 0.580 |
Why?
|
| Thromboembolism | 2 | 2008 | 155 | 0.570 |
Why?
|
| Preoperative Period | 7 | 2018 | 344 | 0.570 |
Why?
|
| Sp1 Transcription Factor | 6 | 2007 | 188 | 0.570 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2015 | 749 | 0.560 |
Why?
|
| Multivariate Analysis | 25 | 2018 | 4298 | 0.560 |
Why?
|
| Precancerous Conditions | 6 | 2023 | 1058 | 0.560 |
Why?
|
| Palliative Care | 11 | 2022 | 2037 | 0.560 |
Why?
|
| Genomics | 7 | 2023 | 2738 | 0.560 |
Why?
|
| Cell Differentiation | 9 | 2017 | 4078 | 0.560 |
Why?
|
| Capecitabine | 9 | 2023 | 388 | 0.560 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2020 | 3821 | 0.550 |
Why?
|
| Patient Selection | 6 | 2017 | 2055 | 0.550 |
Why?
|
| Multimodal Imaging | 4 | 2015 | 550 | 0.540 |
Why?
|
| United States | 28 | 2022 | 15433 | 0.540 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2007 | 363 | 0.540 |
Why?
|
| Cyclin D1 | 3 | 2007 | 576 | 0.540 |
Why?
|
| Proton Therapy | 8 | 2020 | 1577 | 0.540 |
Why?
|
| Biomedical Research | 3 | 2009 | 806 | 0.540 |
Why?
|
| Carcinoma, Islet Cell | 7 | 2005 | 35 | 0.540 |
Why?
|
| Uracil | 6 | 2004 | 64 | 0.540 |
Why?
|
| Young Adult | 27 | 2021 | 21445 | 0.540 |
Why?
|
| Immunoconjugates | 3 | 2023 | 279 | 0.540 |
Why?
|
| Neoplasm Grading | 9 | 2017 | 1742 | 0.530 |
Why?
|
| Piperazines | 3 | 2019 | 2101 | 0.530 |
Why?
|
| Claudins | 3 | 2024 | 47 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2014 | 4549 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2022 | 1249 | 0.510 |
Why?
|
| Predictive Value of Tests | 18 | 2020 | 4892 | 0.510 |
Why?
|
| Treatment Refusal | 2 | 2013 | 128 | 0.510 |
Why?
|
| Precision Medicine | 2 | 2022 | 1154 | 0.510 |
Why?
|
| Deoxycytidine | 6 | 2011 | 1353 | 0.510 |
Why?
|
| Endoscopy | 1 | 2018 | 479 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 17 | 2021 | 3981 | 0.500 |
Why?
|
| Clinical Trials, Phase II as Topic | 7 | 2019 | 665 | 0.500 |
Why?
|
| Isoenzymes | 2 | 2015 | 614 | 0.500 |
Why?
|
| Octreotide | 5 | 2010 | 118 | 0.490 |
Why?
|
| Reoperation | 3 | 2016 | 1382 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1493 | 0.490 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.490 |
Why?
|
| Cell Nucleus | 4 | 2017 | 1620 | 0.480 |
Why?
|
| Aniline Compounds | 1 | 2015 | 177 | 0.480 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2020 | 962 | 0.480 |
Why?
|
| Risk Assessment | 20 | 2020 | 6869 | 0.480 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 1555 | 0.480 |
Why?
|
| Neoplasm Proteins | 9 | 2020 | 3230 | 0.480 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 7222 | 0.480 |
Why?
|
| Up-Regulation | 4 | 2020 | 2450 | 0.470 |
Why?
|
| Risk Factors | 35 | 2020 | 17523 | 0.470 |
Why?
|
| Oncology Nursing | 3 | 2009 | 51 | 0.470 |
Why?
|
| Mice, Nude | 14 | 2020 | 4307 | 0.470 |
Why?
|
| Mutation | 13 | 2023 | 15179 | 0.460 |
Why?
|
| Administration, Oral | 11 | 2017 | 1544 | 0.460 |
Why?
|
| Time Factors | 27 | 2020 | 12926 | 0.460 |
Why?
|
| Databases, Factual | 10 | 2020 | 2218 | 0.460 |
Why?
|
| Meta-Analysis as Topic | 4 | 2010 | 276 | 0.460 |
Why?
|
| Hepatic Artery | 9 | 2018 | 240 | 0.460 |
Why?
|
| Cell Culture Techniques | 3 | 2021 | 598 | 0.460 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 11538 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2017 | 7551 | 0.450 |
Why?
|
| Brain Neoplasms | 5 | 2020 | 4849 | 0.440 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 17 | 0.440 |
Why?
|
| Ki-67 Antigen | 3 | 2016 | 666 | 0.440 |
Why?
|
| Logistic Models | 12 | 2020 | 3441 | 0.440 |
Why?
|
| Drug Evaluation | 29 | 1994 | 425 | 0.430 |
Why?
|
| Macrophages | 3 | 2019 | 1304 | 0.430 |
Why?
|
| Comorbidity | 3 | 2016 | 2352 | 0.420 |
Why?
|
| Chemoembolization, Therapeutic | 6 | 2009 | 181 | 0.420 |
Why?
|
| Biological Products | 1 | 2015 | 274 | 0.410 |
Why?
|
| Endonucleases | 4 | 2019 | 178 | 0.400 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1070 | 0.400 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 1085 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2016 | 419 | 0.400 |
Why?
|
| DNA Copy Number Variations | 5 | 2021 | 1516 | 0.400 |
Why?
|
| Radiopharmaceuticals | 8 | 2020 | 1301 | 0.400 |
Why?
|
| Helicobacter Infections | 4 | 2017 | 1216 | 0.380 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2023 | 107 | 0.370 |
Why?
|
| Gastric Outlet Obstruction | 2 | 2020 | 31 | 0.370 |
Why?
|
| Cancer Survivors | 1 | 2017 | 650 | 0.370 |
Why?
|
| Cytoreduction Surgical Procedures | 5 | 2024 | 475 | 0.370 |
Why?
|
| Gastric Mucosa | 7 | 2021 | 613 | 0.360 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 2315 | 0.360 |
Why?
|
| Colonic Neoplasms | 14 | 1993 | 1390 | 0.360 |
Why?
|
| Genes, ras | 2 | 2010 | 667 | 0.350 |
Why?
|
| Apoptosis | 7 | 2021 | 7591 | 0.350 |
Why?
|
| Propensity Score | 9 | 2021 | 750 | 0.350 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 482 | 0.340 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 966 | 0.340 |
Why?
|
| Esophageal Diseases | 2 | 2006 | 69 | 0.340 |
Why?
|
| Proteomics | 6 | 2024 | 1380 | 0.340 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2022 | 1048 | 0.340 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2006 | 102 | 0.330 |
Why?
|
| Statistics, Nonparametric | 6 | 2020 | 980 | 0.330 |
Why?
|
| Chromosomal Instability | 2 | 2020 | 233 | 0.330 |
Why?
|
| Integrin beta1 | 2 | 2020 | 126 | 0.330 |
Why?
|
| Peritoneal Lavage | 2 | 2019 | 21 | 0.320 |
Why?
|
| Carcinogenesis | 4 | 2024 | 1026 | 0.320 |
Why?
|
| Deglutition Disorders | 5 | 2022 | 447 | 0.320 |
Why?
|
| Cyclooxygenase 2 | 2 | 2007 | 483 | 0.320 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2020 | 340 | 0.320 |
Why?
|
| Diarrhea | 6 | 2010 | 686 | 0.320 |
Why?
|
| Overweight | 1 | 2011 | 484 | 0.320 |
Why?
|
| Data Display | 1 | 2007 | 49 | 0.310 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 195 | 0.310 |
Why?
|
| Sex Factors | 8 | 2016 | 2139 | 0.310 |
Why?
|
| Epirubicin | 5 | 2021 | 157 | 0.310 |
Why?
|
| DNA, Neoplasm | 4 | 2019 | 1910 | 0.310 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 697 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 2341 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 22 | 2019 | 4938 | 0.310 |
Why?
|
| Double-Blind Method | 8 | 2023 | 2588 | 0.310 |
Why?
|
| Intestinal Neoplasms | 3 | 2008 | 189 | 0.300 |
Why?
|
| Quinazolines | 3 | 2006 | 923 | 0.300 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 651 | 0.300 |
Why?
|
| Doxorubicin | 14 | 2004 | 3005 | 0.300 |
Why?
|
| Radiotherapy, Conformal | 5 | 2022 | 902 | 0.300 |
Why?
|
| Antidiarrheals | 3 | 2010 | 37 | 0.300 |
Why?
|
| Peritoneum | 4 | 2024 | 150 | 0.300 |
Why?
|
| Body Mass Index | 3 | 2013 | 2203 | 0.300 |
Why?
|
| Decision Trees | 4 | 2016 | 178 | 0.300 |
Why?
|
| Phenotype | 6 | 2017 | 6295 | 0.290 |
Why?
|
| Drugs, Investigational | 1 | 2008 | 135 | 0.290 |
Why?
|
| Genomic Instability | 2 | 2007 | 519 | 0.290 |
Why?
|
| Transforming Growth Factor beta | 4 | 2018 | 1130 | 0.290 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2019 | 297 | 0.290 |
Why?
|
| Glutarates | 1 | 2006 | 44 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 5 | 2009 | 634 | 0.280 |
Why?
|
| Gastrins | 2 | 2006 | 55 | 0.280 |
Why?
|
| Epothilones | 1 | 2006 | 54 | 0.280 |
Why?
|
| Drug Design | 1 | 2009 | 375 | 0.280 |
Why?
|
| Sulfonamides | 1 | 2015 | 1823 | 0.280 |
Why?
|
| Macrolides | 1 | 2006 | 62 | 0.280 |
Why?
|
| Gene Editing | 2 | 2020 | 216 | 0.280 |
Why?
|
| ras Proteins | 1 | 2010 | 770 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 5 | 2016 | 543 | 0.270 |
Why?
|
| Perfusion | 3 | 2024 | 293 | 0.260 |
Why?
|
| Pathology, Clinical | 2 | 2016 | 152 | 0.260 |
Why?
|
| CRISPR-Cas Systems | 2 | 2020 | 323 | 0.260 |
Why?
|
| Nasolacrimal Duct | 1 | 2005 | 53 | 0.260 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2005 | 53 | 0.260 |
Why?
|
| Intestine, Small | 3 | 2008 | 499 | 0.260 |
Why?
|
| Eflornithine | 8 | 1991 | 59 | 0.260 |
Why?
|
| CTLA-4 Antigen | 2 | 2021 | 657 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2023 | 992 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 5 | 2013 | 2403 | 0.260 |
Why?
|
| Sensitivity and Specificity | 12 | 2017 | 4971 | 0.260 |
Why?
|
| Cancer Care Facilities | 3 | 2020 | 884 | 0.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 1724 | 0.250 |
Why?
|
| Weight Loss | 2 | 2020 | 627 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 2027 | 0.250 |
Why?
|
| Metformin | 3 | 2014 | 378 | 0.250 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 152 | 0.250 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 87 | 0.250 |
Why?
|
| Disease Management | 3 | 2015 | 1052 | 0.250 |
Why?
|
| Biopsy, Needle | 6 | 2007 | 1363 | 0.250 |
Why?
|
| Cause of Death | 4 | 2015 | 752 | 0.240 |
Why?
|
| Professional Staff Committees | 2 | 2001 | 30 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2014 | 5539 | 0.240 |
Why?
|
| Organs at Risk | 3 | 2012 | 514 | 0.240 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 1323 | 0.240 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2005 | 436 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 2488 | 0.240 |
Why?
|
| Therapeutics | 1 | 2003 | 34 | 0.240 |
Why?
|
| CD47 Antigen | 1 | 2023 | 26 | 0.240 |
Why?
|
| Adenoma, Islet Cell | 4 | 1998 | 27 | 0.240 |
Why?
|
| Area Under Curve | 3 | 2020 | 700 | 0.230 |
Why?
|
| DNA Methylation | 6 | 2021 | 2669 | 0.230 |
Why?
|
| Biopsy | 8 | 2020 | 3443 | 0.230 |
Why?
|
| Carbamates | 2 | 1997 | 77 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 5319 | 0.230 |
Why?
|
| Blotting, Western | 9 | 2015 | 3536 | 0.230 |
Why?
|
| Biomarkers | 5 | 2022 | 5047 | 0.230 |
Why?
|
| Research Design | 6 | 2011 | 1544 | 0.220 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2016 | 716 | 0.220 |
Why?
|
| Antigens, Differentiation | 1 | 2023 | 238 | 0.220 |
Why?
|
| Phagocytosis | 1 | 2023 | 260 | 0.220 |
Why?
|
| Thrombocytopenia | 7 | 2017 | 846 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 6 | 2024 | 1290 | 0.220 |
Why?
|
| Drug Monitoring | 4 | 2009 | 333 | 0.220 |
Why?
|
| Cetuximab | 2 | 2016 | 472 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 2 | 2015 | 430 | 0.210 |
Why?
|
| Nephritis | 1 | 2022 | 36 | 0.210 |
Why?
|
| Radiation Injuries | 5 | 2017 | 1411 | 0.210 |
Why?
|
| Premedication | 3 | 2008 | 135 | 0.210 |
Why?
|
| Polyamines | 8 | 1992 | 75 | 0.210 |
Why?
|
| Microsatellite Repeats | 2 | 2019 | 575 | 0.210 |
Why?
|
| Esophageal Stenosis | 1 | 2022 | 83 | 0.210 |
Why?
|
| Drug Therapy | 3 | 2011 | 205 | 0.210 |
Why?
|
| Radiation Pneumonitis | 3 | 2009 | 301 | 0.210 |
Why?
|
| Confidence Intervals | 5 | 2014 | 756 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2023 | 2232 | 0.210 |
Why?
|
| Neoplasm Transplantation | 5 | 2021 | 1519 | 0.210 |
Why?
|
| Leukocytes | 3 | 2014 | 422 | 0.210 |
Why?
|
| Thioguanine | 2 | 1991 | 68 | 0.200 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2003 | 167 | 0.200 |
Why?
|
| Age Factors | 6 | 2016 | 5377 | 0.200 |
Why?
|
| Stomach Diseases | 1 | 2021 | 62 | 0.200 |
Why?
|
| Models, Biological | 3 | 2019 | 3254 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 2508 | 0.190 |
Why?
|
| Fusobacterium Infections | 1 | 2020 | 28 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 5 | 2020 | 3101 | 0.190 |
Why?
|
| Gene Regulatory Networks | 3 | 2021 | 677 | 0.190 |
Why?
|
| Annexin A6 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Hypertension | 2 | 2024 | 1503 | 0.190 |
Why?
|
| Genotype | 6 | 2019 | 4109 | 0.190 |
Why?
|
| Cell Movement | 5 | 2019 | 2466 | 0.190 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 82 | 0.190 |
Why?
|
| Thymidylate Synthase | 2 | 2014 | 53 | 0.190 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 35 | 0.190 |
Why?
|
| Interferon-alpha | 10 | 2008 | 889 | 0.190 |
Why?
|
| Galectins | 2 | 2017 | 71 | 0.190 |
Why?
|
| Bevacizumab | 2 | 2019 | 938 | 0.190 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 126 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 290 | 0.190 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 22 | 0.190 |
Why?
|
| Perineum | 1 | 2021 | 107 | 0.190 |
Why?
|
| Pathologists | 1 | 2021 | 91 | 0.190 |
Why?
|
| Analysis of Variance | 10 | 2015 | 2307 | 0.180 |
Why?
|
| DNA Repair | 4 | 2020 | 1872 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 945 | 0.180 |
Why?
|
| Embolization, Therapeutic | 5 | 2005 | 551 | 0.180 |
Why?
|
| Radiation Oncology | 2 | 2002 | 529 | 0.180 |
Why?
|
| Radiography | 8 | 2013 | 1904 | 0.180 |
Why?
|
| Health Promotion | 1 | 2004 | 502 | 0.180 |
Why?
|
| Stromal Cells | 3 | 2023 | 825 | 0.180 |
Why?
|
| Mucous Membrane | 4 | 2015 | 271 | 0.180 |
Why?
|
| Mannose | 2 | 2017 | 40 | 0.180 |
Why?
|
| Linitis Plastica | 1 | 2019 | 13 | 0.180 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2020 | 111 | 0.180 |
Why?
|
| Vaccination | 1 | 2006 | 1123 | 0.180 |
Why?
|
| Gene Amplification | 2 | 2020 | 731 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2022 | 289 | 0.180 |
Why?
|
| Linear Models | 4 | 2017 | 1085 | 0.180 |
Why?
|
| Blood Proteins | 2 | 2017 | 294 | 0.180 |
Why?
|
| Japan | 2 | 2017 | 227 | 0.180 |
Why?
|
| Adult Stem Cells | 1 | 2020 | 73 | 0.170 |
Why?
|
| Lentivirus | 1 | 2020 | 169 | 0.170 |
Why?
|
| Transfection | 5 | 2017 | 2944 | 0.170 |
Why?
|
| Pilot Projects | 5 | 2021 | 2803 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 425 | 0.170 |
Why?
|
| Cell Cycle | 4 | 2018 | 2084 | 0.170 |
Why?
|
| Benchmarking | 1 | 2021 | 273 | 0.170 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2019 | 83 | 0.170 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 187 | 0.170 |
Why?
|
| DNA Mismatch Repair | 2 | 2018 | 268 | 0.170 |
Why?
|
| Ploidies | 1 | 2019 | 248 | 0.170 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 83 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 15 | 0.170 |
Why?
|
| Intestinal Mucosa | 4 | 2020 | 1081 | 0.170 |
Why?
|
| Gene Expression | 5 | 2019 | 3570 | 0.170 |
Why?
|
| Febrile Neutropenia | 2 | 2017 | 65 | 0.170 |
Why?
|
| Primary Cell Culture | 2 | 2020 | 208 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2024 | 493 | 0.170 |
Why?
|
| Cell Survival | 11 | 2017 | 3045 | 0.170 |
Why?
|
| Malignant Carcinoid Syndrome | 3 | 1999 | 39 | 0.170 |
Why?
|
| Colony-Forming Units Assay | 7 | 1988 | 249 | 0.160 |
Why?
|
| Telomere | 2 | 2014 | 505 | 0.160 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 159 | 0.160 |
Why?
|
| Protein Binding | 4 | 2019 | 3438 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 430 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 2054 | 0.160 |
Why?
|
| Neoplasms, Experimental | 3 | 2020 | 750 | 0.160 |
Why?
|
| Forecasting | 4 | 2009 | 694 | 0.160 |
Why?
|
| Gastroplasty | 1 | 2018 | 22 | 0.160 |
Why?
|
| Epigenomics | 2 | 2023 | 266 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 135 | 0.160 |
Why?
|
| Cadherins | 4 | 2024 | 660 | 0.160 |
Why?
|
| Oncogenes | 2 | 2020 | 673 | 0.160 |
Why?
|
| Pylorus | 1 | 2018 | 28 | 0.160 |
Why?
|
| Cell Dedifferentiation | 1 | 2018 | 96 | 0.160 |
Why?
|
| Nuclear Proteins | 4 | 2023 | 3343 | 0.160 |
Why?
|
| Bayes Theorem | 3 | 2024 | 1021 | 0.160 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2017 | 23 | 0.160 |
Why?
|
| Immune System | 2 | 2019 | 279 | 0.160 |
Why?
|
| Recombinant Proteins | 14 | 2008 | 2927 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.160 |
Why?
|
| Plasmids | 1 | 2020 | 837 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 561 | 0.160 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2017 | 76 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2018 | 223 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2021 | 2086 | 0.150 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 459 | 0.150 |
Why?
|
| Drug Synergism | 3 | 2015 | 1313 | 0.150 |
Why?
|
| Republic of Korea | 1 | 2017 | 70 | 0.150 |
Why?
|
| Thiobarbiturates | 2 | 1994 | 3 | 0.150 |
Why?
|
| Drug Discovery | 2 | 2019 | 324 | 0.150 |
Why?
|
| Vidarabine Phosphate | 2 | 1988 | 50 | 0.150 |
Why?
|
| Arabinonucleotides | 2 | 1988 | 71 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2016 | 1335 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2000 | 408 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2017 | 128 | 0.150 |
Why?
|
| RNA-Binding Proteins | 2 | 2020 | 984 | 0.150 |
Why?
|
| Floxuridine | 4 | 2004 | 38 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 10 | 2013 | 5395 | 0.150 |
Why?
|
| Maytansine | 1 | 2017 | 38 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2016 | 17 | 0.150 |
Why?
|
| Interferon-gamma | 5 | 2020 | 1144 | 0.150 |
Why?
|
| Tumor Stem Cell Assay | 6 | 1988 | 231 | 0.150 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 71 | 0.150 |
Why?
|
| Breast Neoplasms | 8 | 2015 | 15694 | 0.150 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1005 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 810 | 0.140 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2018 | 94 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2016 | 132 | 0.140 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2008 | 295 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2017 | 64 | 0.140 |
Why?
|
| Bile Acids and Salts | 2 | 2009 | 246 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2009 | 327 | 0.140 |
Why?
|
| Glucagonoma | 2 | 1994 | 11 | 0.140 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.140 |
Why?
|
| Postoperative Period | 2 | 2013 | 665 | 0.140 |
Why?
|
| Cytokines | 2 | 2017 | 2809 | 0.140 |
Why?
|
| Photons | 2 | 2017 | 507 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2007 | 726 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2016 | 212 | 0.140 |
Why?
|
| Flavonoids | 1 | 2017 | 188 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 69 | 0.140 |
Why?
|
| Mesoderm | 1 | 2018 | 404 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1999 | 408 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2019 | 690 | 0.140 |
Why?
|
| Probability | 3 | 2007 | 866 | 0.140 |
Why?
|
| Genetic Vectors | 2 | 2020 | 1694 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1586 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2015 | 1678 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 75 | 0.130 |
Why?
|
| Lymphopenia | 1 | 2017 | 199 | 0.130 |
Why?
|
| Drug Delivery Systems | 3 | 2009 | 669 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 598 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.130 |
Why?
|
| Genetic Markers | 2 | 2017 | 974 | 0.130 |
Why?
|
| Porphyrins | 1 | 2015 | 37 | 0.130 |
Why?
|
| Case-Control Studies | 10 | 2015 | 6100 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 904 | 0.130 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 335 | 0.130 |
Why?
|
| Adolescent | 13 | 2019 | 31252 | 0.130 |
Why?
|
| Odds Ratio | 6 | 2014 | 2316 | 0.130 |
Why?
|
| Incidence | 6 | 2020 | 5673 | 0.130 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 6009 | 0.130 |
Why?
|
| Algorithms | 4 | 2017 | 3890 | 0.130 |
Why?
|
| Heterografts | 4 | 2022 | 733 | 0.130 |
Why?
|
| DNA, Mitochondrial | 2 | 2014 | 311 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2003 | 1112 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 1823 | 0.130 |
Why?
|
| Gastric Bypass | 1 | 2015 | 81 | 0.130 |
Why?
|
| Stem Cells | 2 | 2016 | 1213 | 0.130 |
Why?
|
| Exosomes | 1 | 2017 | 253 | 0.130 |
Why?
|
| Microfilament Proteins | 2 | 2019 | 487 | 0.130 |
Why?
|
| Pyrazines | 1 | 1997 | 495 | 0.130 |
Why?
|
| Genome-Wide Association Study | 4 | 2017 | 2265 | 0.120 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 277 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 7 | 2016 | 2370 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 3154 | 0.120 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2015 | 153 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 1217 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2016 | 351 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 5 | 2011 | 503 | 0.120 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 615 | 0.120 |
Why?
|
| Autophagy | 1 | 2020 | 927 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 577 | 0.120 |
Why?
|
| Forearm Injuries | 1 | 1994 | 6 | 0.120 |
Why?
|
| Nursing Assessment | 3 | 2009 | 42 | 0.120 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1994 | 22 | 0.120 |
Why?
|
| Diagnostic Imaging | 5 | 2009 | 1162 | 0.120 |
Why?
|
| Histones | 2 | 2013 | 1466 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 1215 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2021 | 1818 | 0.120 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2005 | 365 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 7 | 1988 | 1242 | 0.120 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 275 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 249 | 0.120 |
Why?
|
| Methotrexate | 7 | 2001 | 999 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2015 | 875 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 1994 | 57 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.120 |
Why?
|
| Transcriptome | 4 | 2016 | 1859 | 0.120 |
Why?
|
| Carrier Proteins | 3 | 2013 | 2022 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2024 | 2359 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4143 | 0.120 |
Why?
|
| Survival | 2 | 2005 | 177 | 0.120 |
Why?
|
| Organizational Objectives | 3 | 2002 | 61 | 0.120 |
Why?
|
| Regression Analysis | 3 | 2017 | 1546 | 0.120 |
Why?
|
| Jejunostomy | 3 | 2020 | 52 | 0.110 |
Why?
|
| Genome, Human | 1 | 2021 | 1869 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 663 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 5 | 2009 | 1165 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2013 | 275 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 607 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 573 | 0.110 |
Why?
|
| Haplotypes | 5 | 2014 | 856 | 0.110 |
Why?
|
| Drug Approval | 1 | 2014 | 178 | 0.110 |
Why?
|
| Stomach Rupture | 2 | 2002 | 5 | 0.110 |
Why?
|
| Imides | 2 | 1991 | 10 | 0.110 |
Why?
|
| Ornithine | 5 | 1992 | 40 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2014 | 699 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2022 | 1375 | 0.110 |
Why?
|
| beta Catenin | 1 | 2016 | 688 | 0.110 |
Why?
|
| Gastroenterology | 1 | 2015 | 195 | 0.110 |
Why?
|
| Lung | 7 | 2012 | 3151 | 0.110 |
Why?
|
| Recurrence | 4 | 2012 | 4758 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2020 | 2819 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2021 | 641 | 0.110 |
Why?
|
| Gastroscopy | 1 | 2012 | 134 | 0.110 |
Why?
|
| Smad3 Protein | 1 | 2013 | 129 | 0.110 |
Why?
|
| Pneumonia | 3 | 2017 | 751 | 0.110 |
Why?
|
| Bone Marrow Diseases | 2 | 1993 | 177 | 0.110 |
Why?
|
| Stents | 3 | 2022 | 1096 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 598 | 0.100 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 1084 | 0.100 |
Why?
|
| Safety | 2 | 2007 | 465 | 0.100 |
Why?
|
| Parenteral Nutrition, Total | 5 | 1992 | 140 | 0.100 |
Why?
|
| Liver | 6 | 2016 | 2961 | 0.100 |
Why?
|
| Isoquinolines | 2 | 1991 | 116 | 0.100 |
Why?
|
| RNA, Small Interfering | 7 | 2017 | 2216 | 0.100 |
Why?
|
| Galectin 4 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 131 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 218 | 0.100 |
Why?
|
| Piperidines | 1 | 2017 | 1035 | 0.100 |
Why?
|
| Deoxyglucose | 1 | 2011 | 115 | 0.100 |
Why?
|
| Sirolimus | 2 | 2013 | 814 | 0.100 |
Why?
|
| Nurse's Role | 2 | 2008 | 42 | 0.100 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 316 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 586 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2009 | 292 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2017 | 6150 | 0.100 |
Why?
|
| Decision Making | 2 | 2017 | 1287 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 3869 | 0.100 |
Why?
|
| Fibrosarcoma | 5 | 1989 | 135 | 0.100 |
Why?
|
| Computer Graphics | 1 | 2010 | 82 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 1833 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 4757 | 0.090 |
Why?
|
| Interprofessional Relations | 2 | 2004 | 213 | 0.090 |
Why?
|
| Clinical Protocols | 2 | 2008 | 467 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.090 |
Why?
|
| Patient Care | 1 | 2011 | 149 | 0.090 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2010 | 209 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2013 | 747 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2007 | 191 | 0.090 |
Why?
|
| Feasibility Studies | 5 | 2004 | 2292 | 0.090 |
Why?
|
| Alkaloids | 3 | 1987 | 75 | 0.090 |
Why?
|
| Obesity | 2 | 2013 | 2884 | 0.090 |
Why?
|
| Europe | 2 | 2003 | 649 | 0.090 |
Why?
|
| Ablation Techniques | 1 | 2011 | 148 | 0.090 |
Why?
|
| Severity of Illness Index | 6 | 2010 | 4320 | 0.090 |
Why?
|
| Lignans | 1 | 2009 | 15 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 674 | 0.090 |
Why?
|
| Spiro Compounds | 3 | 1987 | 58 | 0.090 |
Why?
|
| Peptides | 2 | 2013 | 1479 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 347 | 0.090 |
Why?
|
| Laparotomy | 3 | 2020 | 211 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 130 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 3639 | 0.090 |
Why?
|
| Mercaptoethanol | 1 | 1988 | 17 | 0.090 |
Why?
|
| Erythrocytes | 6 | 1992 | 339 | 0.090 |
Why?
|
| Mesna | 1 | 1988 | 65 | 0.080 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.080 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 2 | 2005 | 96 | 0.080 |
Why?
|
| Nausea | 7 | 2011 | 525 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2010 | 286 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 1994 | 493 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 172 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2013 | 1385 | 0.080 |
Why?
|
| Nurse Clinicians | 1 | 2008 | 5 | 0.080 |
Why?
|
| Clinical Nursing Research | 1 | 2008 | 8 | 0.080 |
Why?
|
| Harringtonines | 2 | 1986 | 92 | 0.080 |
Why?
|
| Multigene Family | 2 | 2007 | 425 | 0.080 |
Why?
|
| Organometallic Compounds | 3 | 1987 | 191 | 0.080 |
Why?
|
| 3' Untranslated Regions | 2 | 2009 | 343 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2016 | 1589 | 0.080 |
Why?
|
| Total Quality Management | 1 | 2008 | 34 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 185 | 0.080 |
Why?
|
| Adenine | 3 | 2007 | 631 | 0.080 |
Why?
|
| Medical Records | 3 | 2005 | 415 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 129 | 0.080 |
Why?
|
| Anal Canal | 1 | 2009 | 238 | 0.080 |
Why?
|
| Ifosfamide | 1 | 1988 | 344 | 0.080 |
Why?
|
| CpG Islands | 2 | 2013 | 633 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 194 | 0.080 |
Why?
|
| Coculture Techniques | 2 | 2020 | 626 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2008 | 100 | 0.080 |
Why?
|
| Povidone | 1 | 1987 | 13 | 0.080 |
Why?
|
| Cluster Analysis | 4 | 2013 | 1053 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2019 | 566 | 0.080 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 402 | 0.080 |
Why?
|
| Binding Sites | 3 | 2019 | 2171 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 602 | 0.070 |
Why?
|
| Niacinamide | 1 | 2009 | 421 | 0.070 |
Why?
|
| DNA Damage | 3 | 2020 | 1954 | 0.070 |
Why?
|
| Esophageal Fistula | 1 | 2007 | 27 | 0.070 |
Why?
|
| Heart | 5 | 2012 | 1223 | 0.070 |
Why?
|
| Neutropenia | 4 | 2009 | 968 | 0.070 |
Why?
|
| Isoindoles | 1 | 2006 | 11 | 0.070 |
Why?
|
| Bryostatins | 1 | 2006 | 12 | 0.070 |
Why?
|
| Dideoxynucleosides | 1 | 2006 | 19 | 0.070 |
Why?
|
| Hospitals, Community | 1 | 2007 | 79 | 0.070 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 62 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 120 | 0.070 |
Why?
|
| Research | 1 | 2009 | 415 | 0.070 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 69 | 0.070 |
Why?
|
| Pathology | 1 | 2007 | 101 | 0.070 |
Why?
|
| Genes, MDR | 1 | 2006 | 38 | 0.070 |
Why?
|
| International Agencies | 1 | 2006 | 107 | 0.070 |
Why?
|
| Research Personnel | 1 | 2008 | 156 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 151 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 2576 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 204 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2008 | 748 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2008 | 393 | 0.070 |
Why?
|
| Mitochondria | 1 | 2013 | 1282 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 2 | 2008 | 334 | 0.070 |
Why?
|
| Hand Dermatoses | 1 | 1985 | 25 | 0.070 |
Why?
|
| Foot Dermatoses | 1 | 1985 | 23 | 0.070 |
Why?
|
| Comet Assay | 1 | 2005 | 59 | 0.070 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 81 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 78 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 706 | 0.070 |
Why?
|
| Drug Eruptions | 3 | 1994 | 256 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 672 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 298 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 241 | 0.070 |
Why?
|
| Fatigue | 2 | 2022 | 1239 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2020 | 3033 | 0.070 |
Why?
|
| Intubation | 1 | 2005 | 40 | 0.070 |
Why?
|
| Time | 1 | 2006 | 178 | 0.070 |
Why?
|
| Drug Resistance | 3 | 2022 | 587 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2020 | 1869 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2011 | 992 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2006 | 604 | 0.070 |
Why?
|
| Demography | 2 | 2013 | 435 | 0.070 |
Why?
|
| Metaplasia | 1 | 2007 | 383 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 1986 | 237 | 0.070 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 17 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2005 | 24 | 0.070 |
Why?
|
| Streptozocin | 3 | 2004 | 75 | 0.070 |
Why?
|
| Dacryocystorhinostomy | 1 | 2005 | 44 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2006 | 149 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 580 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2005 | 90 | 0.070 |
Why?
|
| Social Support | 1 | 2008 | 560 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2016 | 1555 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 125 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2006 | 270 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2005 | 176 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2005 | 108 | 0.060 |
Why?
|
| Jejunal Neoplasms | 1 | 2004 | 34 | 0.060 |
Why?
|
| Ileal Neoplasms | 1 | 2004 | 47 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2314 | 0.060 |
Why?
|
| Thoracic Neoplasms | 2 | 2015 | 337 | 0.060 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2024 | 35 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 260 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2005 | 311 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.060 |
Why?
|
| Prevalence | 1 | 2012 | 3260 | 0.060 |
Why?
|
| Cyclins | 1 | 2005 | 456 | 0.060 |
Why?
|
| Gastrostomy | 2 | 2020 | 180 | 0.060 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 3 | 1990 | 15 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 314 | 0.060 |
Why?
|
| Ecotype | 1 | 2023 | 9 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 874 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2004 | 138 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1331 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1054 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 521 | 0.060 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 138 | 0.060 |
Why?
|
| Radionuclide Imaging | 2 | 2003 | 660 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 495 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 986 | 0.060 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2023 | 46 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2008 | 551 | 0.060 |
Why?
|
| Digestive System Neoplasms | 2 | 2009 | 82 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1870 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1960 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 246 | 0.060 |
Why?
|
| Age of Onset | 1 | 2005 | 827 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 148 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 2011 | 682 | 0.060 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 33 | 0.050 |
Why?
|
| Statistics as Topic | 3 | 2010 | 445 | 0.050 |
Why?
|
| Altretamine | 1 | 1982 | 4 | 0.050 |
Why?
|
| Bleomycin | 3 | 1990 | 467 | 0.050 |
Why?
|
| Technology, Radiologic | 1 | 2002 | 80 | 0.050 |
Why?
|
| Patient Generated Health Data | 1 | 2022 | 2 | 0.050 |
Why?
|
| Base Sequence | 3 | 2020 | 4917 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2024 | 245 | 0.050 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1995 | 222 | 0.050 |
Why?
|
| Vinblastine | 1 | 2003 | 453 | 0.050 |
Why?
|
| Vomiting | 4 | 2000 | 354 | 0.050 |
Why?
|
| Tissue Array Analysis | 3 | 2011 | 760 | 0.050 |
Why?
|
| Agranulocytosis | 4 | 1995 | 79 | 0.050 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2002 | 103 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2008 | 726 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2020 | 709 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 349 | 0.050 |
Why?
|
| Indians, North American | 1 | 2002 | 87 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 462 | 0.050 |
Why?
|
| Cyclin E | 1 | 2023 | 267 | 0.050 |
Why?
|
| Triazines | 1 | 1982 | 117 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 285 | 0.050 |
Why?
|
| Benzamides | 1 | 2007 | 1832 | 0.050 |
Why?
|
| Azoxymethane | 1 | 2020 | 43 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2018 | 178 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 285 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2000 | 27 | 0.050 |
Why?
|
| Rats, Inbred F344 | 9 | 1992 | 224 | 0.050 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2020 | 27 | 0.050 |
Why?
|
| Dextrans | 1 | 2020 | 90 | 0.050 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 68 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2020 | 13 | 0.050 |
Why?
|
| Lewis X Antigen | 1 | 2000 | 46 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 260 | 0.050 |
Why?
|
| Coenzyme A Ligases | 1 | 2020 | 14 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2014 | 355 | 0.050 |
Why?
|
| Glutathione Peroxidase | 1 | 2020 | 61 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2020 | 348 | 0.050 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2020 | 31 | 0.050 |
Why?
|
| Graft Survival | 1 | 2003 | 1062 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2020 | 355 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.040 |
Why?
|
| Levoleucovorin | 1 | 1999 | 2 | 0.040 |
Why?
|
| Drug Hypersensitivity | 3 | 2009 | 128 | 0.040 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2020 | 104 | 0.040 |
Why?
|
| Asia | 1 | 1999 | 142 | 0.040 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2019 | 13 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2021 | 403 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2006 | 860 | 0.040 |
Why?
|
| Sirtuins | 1 | 2019 | 44 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 717 | 0.040 |
Why?
|
| Alleles | 2 | 2019 | 2437 | 0.040 |
Why?
|
| Sarcoma | 3 | 1987 | 1725 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 5 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Asthenia | 2 | 2009 | 18 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Genital Neoplasms, Female | 1 | 1986 | 735 | 0.040 |
Why?
|
| Global Health | 1 | 2004 | 657 | 0.040 |
Why?
|
| Digestive System Fistula | 1 | 1998 | 5 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 591 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2020 | 1664 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.040 |
Why?
|
| Proteolysis | 1 | 2020 | 370 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2004 | 795 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 2195 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1982 | 410 | 0.040 |
Why?
|
| Nail Diseases | 2 | 2009 | 40 | 0.040 |
Why?
|
| Respiratory Tract Fistula | 1 | 1998 | 33 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 554 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 1999 | 108 | 0.040 |
Why?
|
| Bone Marrow | 5 | 1988 | 2358 | 0.040 |
Why?
|
| Smad Proteins | 1 | 2018 | 88 | 0.040 |
Why?
|
| Pain | 2 | 2022 | 1658 | 0.040 |
Why?
|
| Celiac Artery | 1 | 2018 | 40 | 0.040 |
Why?
|
| Splenic Artery | 1 | 2018 | 50 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 20 | 0.040 |
Why?
|
| Rats | 10 | 2012 | 6086 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 1999 | 25 | 0.040 |
Why?
|
| RNA Interference | 2 | 2016 | 1408 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 668 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 287 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 694 | 0.040 |
Why?
|
| Helicobacter pylori | 2 | 2004 | 1295 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 509 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 375 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 905 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 126 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1077 | 0.040 |
Why?
|
| Cells, Cultured | 7 | 2005 | 5637 | 0.040 |
Why?
|
| Abdomen | 2 | 2012 | 332 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2009 | 394 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 460 | 0.040 |
Why?
|
| Culture Media | 6 | 1988 | 319 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1997 | 129 | 0.040 |
Why?
|
| China | 1 | 2018 | 606 | 0.040 |
Why?
|
| ROC Curve | 2 | 2011 | 1183 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2012 | 4804 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 545 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 259 | 0.040 |
Why?
|
| Random Allocation | 2 | 1989 | 703 | 0.040 |
Why?
|
| Homeostasis | 1 | 2022 | 950 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 1020 | 0.040 |
Why?
|
| Registries | 1 | 2004 | 2170 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 670 | 0.040 |
Why?
|
| Pyridazines | 1 | 2019 | 293 | 0.040 |
Why?
|
| Body Weight | 3 | 2018 | 1293 | 0.040 |
Why?
|
| Abdominal Neoplasms | 2 | 2015 | 231 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 117 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 315 | 0.030 |
Why?
|
| Ultrasonography | 4 | 1996 | 1863 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 679 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 452 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2000 | 548 | 0.030 |
Why?
|
| Arteries | 1 | 2017 | 274 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 275 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 306 | 0.030 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2015 | 32 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 409 | 0.030 |
Why?
|
| Calcium | 1 | 2022 | 1537 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 342 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 220 | 0.030 |
Why?
|
| Hormones | 2 | 1994 | 266 | 0.030 |
Why?
|
| Mutagens | 2 | 2006 | 187 | 0.030 |
Why?
|
| Pyrazoles | 2 | 2019 | 1471 | 0.030 |
Why?
|
| Gamma Rays | 2 | 2006 | 242 | 0.030 |
Why?
|
| Injections, Intramuscular | 2 | 2010 | 255 | 0.030 |
Why?
|
| Inflammation | 2 | 2019 | 2522 | 0.030 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2014 | 13 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 1996 | 138 | 0.030 |
Why?
|
| Sarcoma, Experimental | 2 | 1991 | 68 | 0.030 |
Why?
|
| Proline | 1 | 2015 | 130 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 2 | 1991 | 31 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2002 | 1270 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 368 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1990 | 1538 | 0.030 |
Why?
|
| Gastrinoma | 1 | 1994 | 25 | 0.030 |
Why?
|
| Aminopterin | 1 | 1994 | 30 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 838 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1995 | 242 | 0.030 |
Why?
|
| Insulinoma | 1 | 1994 | 55 | 0.030 |
Why?
|
| Mucin-1 | 1 | 2014 | 127 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2013 | 110 | 0.030 |
Why?
|
| Cytarabine | 2 | 1995 | 1973 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 397 | 0.030 |
Why?
|
| Laser Scanning Cytometry | 1 | 2013 | 16 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2014 | 200 | 0.030 |
Why?
|
| Anal Gland Neoplasms | 1 | 1993 | 2 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 223 | 0.030 |
Why?
|
| Soft Tissue Injuries | 1 | 1994 | 51 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1993 | 216 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2013 | 64 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 1682 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 134 | 0.030 |
Why?
|
| Anemia | 2 | 2017 | 689 | 0.030 |
Why?
|
| Naphthalimides | 2 | 1991 | 14 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 1491 | 0.030 |
Why?
|
| Rupture, Spontaneous | 2 | 2002 | 70 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 886 | 0.030 |
Why?
|
| Food, Formulated | 1 | 1992 | 50 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 1986 | 4638 | 0.030 |
Why?
|
| Carboplatin | 2 | 2006 | 823 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1994 | 259 | 0.030 |
Why?
|
| Melanoma | 3 | 1987 | 5317 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Nitriles | 2 | 2008 | 906 | 0.030 |
Why?
|
| Necrosis | 1 | 1994 | 580 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 612 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1972 | 0.030 |
Why?
|
| Depsipeptides | 1 | 1992 | 78 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 133 | 0.030 |
Why?
|
| Organophosphonates | 2 | 1991 | 64 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 1062 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2011 | 189 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1992 | 139 | 0.030 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 1996 | 469 | 0.030 |
Why?
|
| Metabolomics | 1 | 2015 | 478 | 0.030 |
Why?
|
| Dehydration | 1 | 2011 | 87 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 413 | 0.020 |
Why?
|
| Consensus | 1 | 2015 | 978 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Everolimus | 1 | 2013 | 415 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.020 |
Why?
|
| Platelet Count | 2 | 1989 | 490 | 0.020 |
Why?
|
| Osteonectin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 1879 | 0.020 |
Why?
|
| Standard of Care | 1 | 2012 | 243 | 0.020 |
Why?
|
| Anorexia | 1 | 2011 | 143 | 0.020 |
Why?
|
| Length of Stay | 3 | 2005 | 1900 | 0.020 |
Why?
|
| Semantics | 1 | 2010 | 58 | 0.020 |
Why?
|
| United Kingdom | 1 | 2001 | 257 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2011 | 202 | 0.020 |
Why?
|
| Systems Integration | 1 | 2010 | 76 | 0.020 |
Why?
|
| Syndrome | 1 | 1994 | 1351 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1986 | 3976 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 1990 | 65 | 0.020 |
Why?
|
| Trimetrexate | 1 | 1990 | 12 | 0.020 |
Why?
|
| Osteopontin | 1 | 2010 | 148 | 0.020 |
Why?
|
| Injections, Subcutaneous | 3 | 1999 | 334 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2014 | 1113 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.020 |
Why?
|
| Clone Cells | 3 | 1986 | 555 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2010 | 135 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2010 | 119 | 0.020 |
Why?
|
| Pancreatic Hormones | 1 | 1989 | 8 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1990 | 114 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 7702 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2009 | 32 | 0.020 |
Why?
|
| Gastrointestinal Hormones | 1 | 1989 | 26 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2009 | 162 | 0.020 |
Why?
|
| Protons | 1 | 2012 | 473 | 0.020 |
Why?
|
| Arginine | 1 | 1992 | 500 | 0.020 |
Why?
|
| Blood | 1 | 1989 | 156 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 745 | 0.020 |
Why?
|
| Granulocytes | 2 | 1986 | 224 | 0.020 |
Why?
|
| Cell Division | 3 | 2008 | 2489 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1988 | 57 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1037 | 0.020 |
Why?
|
| Health Resources | 1 | 2010 | 168 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2008 | 21 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 589 | 0.020 |
Why?
|
| Nursing Research | 1 | 2008 | 18 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2008 | 51 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 1234 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 1987 | 423 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 460 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2009 | 117 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 356 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2283 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2006 | 931 | 0.020 |
Why?
|
| Kidney | 3 | 2011 | 2146 | 0.020 |
Why?
|
| Smoking | 2 | 2008 | 2440 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 432 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 237 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2013 | 717 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 717 | 0.020 |
Why?
|
| Sulfones | 1 | 2008 | 143 | 0.020 |
Why?
|
| Hypotension | 2 | 1986 | 210 | 0.020 |
Why?
|
| Kinetics | 2 | 1987 | 2049 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 6942 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 644 | 0.020 |
Why?
|
| Edema | 1 | 2009 | 267 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2013 | 732 | 0.020 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2008 | 92 | 0.020 |
Why?
|
| Cachexia | 1 | 1988 | 161 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2010 | 690 | 0.020 |
Why?
|
| Biotransformation | 1 | 1986 | 93 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2006 | 41 | 0.020 |
Why?
|
| Epoxy Compounds | 1 | 2006 | 55 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2006 | 65 | 0.020 |
Why?
|
| Tritium | 1 | 2006 | 200 | 0.020 |
Why?
|
| Chromogranins | 1 | 2006 | 84 | 0.020 |
Why?
|
| Nervous System Diseases | 2 | 2009 | 500 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 2001 | 1014 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 1073 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Pyrazolones | 1 | 1986 | 4 | 0.020 |
Why?
|
| Oxazoles | 1 | 1986 | 60 | 0.020 |
Why?
|
| Agar | 1 | 1986 | 26 | 0.020 |
Why?
|
| Metals | 1 | 2007 | 155 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 2074 | 0.020 |
Why?
|
| Butadienes | 1 | 2005 | 35 | 0.020 |
Why?
|
| Adenoma | 1 | 1991 | 716 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1986 | 132 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1982 | 4654 | 0.020 |
Why?
|
| Isoxazoles | 1 | 1986 | 81 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2006 | 133 | 0.020 |
Why?
|
| Azacitidine | 1 | 1992 | 1149 | 0.020 |
Why?
|
| Child | 3 | 2017 | 29154 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 249 | 0.020 |
Why?
|
| Pancreatectomy | 2 | 2004 | 652 | 0.020 |
Why?
|
| Informed Consent | 1 | 2009 | 419 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 597 | 0.020 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2005 | 7 | 0.020 |
Why?
|
| SEER Program | 1 | 2009 | 1000 | 0.020 |
Why?
|
| Fatty Alcohols | 1 | 2005 | 10 | 0.020 |
Why?
|
| Glycols | 1 | 2005 | 8 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1987 | 553 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 299 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2005 | 20 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 12 | 0.020 |
Why?
|
| Fever | 1 | 2008 | 497 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 671 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2004 | 14 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 246 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 2422 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1984 | 164 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 636 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2005 | 206 | 0.020 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2005 | 90 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 301 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 1399 | 0.020 |
Why?
|
| Medicare | 1 | 2009 | 860 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 1082 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 265 | 0.010 |
Why?
|
| Parenteral Nutrition | 1 | 1985 | 207 | 0.010 |
Why?
|
| Splenectomy | 1 | 2004 | 158 | 0.010 |
Why?
|
| Germanium | 1 | 1983 | 7 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2005 | 98 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 310 | 0.010 |
Why?
|
| Software | 1 | 2010 | 1321 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 593 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1982 | 62 | 0.010 |
Why?
|
| Growth Substances | 1 | 1984 | 300 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.010 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2004 | 221 | 0.010 |
Why?
|
| DNA | 2 | 2003 | 2693 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 321 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1986 | 943 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 1274 | 0.010 |
Why?
|
| Biogenic Polyamines | 2 | 1991 | 3 | 0.010 |
Why?
|
| Emergencies | 1 | 2002 | 202 | 0.010 |
Why?
|
| Gastritis | 1 | 2004 | 373 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3203 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 2 | 1993 | 171 | 0.010 |
Why?
|
| Cell Adhesion | 3 | 1988 | 1008 | 0.010 |
Why?
|
| Mortality | 1 | 2002 | 343 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 739 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 1064 | 0.010 |
Why?
|
| Alopecia | 2 | 1994 | 126 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1982 | 436 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 6089 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 620 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1999 | 208 | 0.010 |
Why?
|
| Capsules | 1 | 1998 | 53 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 1121 | 0.010 |
Why?
|
| Polyesters | 1 | 1998 | 53 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1945 | 0.010 |
Why?
|
| Leukopenia | 2 | 1989 | 151 | 0.010 |
Why?
|
| Spleen | 2 | 1991 | 676 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 830 | 0.010 |
Why?
|
| Polymers | 1 | 1998 | 223 | 0.010 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1996 | 27 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 305 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 1021 | 0.010 |
Why?
|
| Codon | 1 | 1996 | 241 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1995 | 158 | 0.010 |
Why?
|
| Equipment Design | 1 | 1998 | 1204 | 0.010 |
Why?
|
| Lymphoma | 1 | 1983 | 1467 | 0.010 |
Why?
|
| Angiography | 1 | 1996 | 360 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 1993 | 40 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1984 | 191 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1992 | 97 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1992 | 216 | 0.010 |
Why?
|
| Pedigree | 1 | 1996 | 1890 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 2992 | 0.010 |
Why?
|
| Stomatitis | 1 | 1992 | 183 | 0.010 |
Why?
|
| Intestine, Large | 1 | 1991 | 28 | 0.010 |
Why?
|
| Intestinal Polyps | 1 | 1991 | 72 | 0.010 |
Why?
|
| Autoradiography | 1 | 1990 | 132 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 418 | 0.010 |
Why?
|
| Magnesium | 1 | 1991 | 160 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1991 | 429 | 0.010 |
Why?
|
| Esophagitis | 1 | 1991 | 202 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1990 | 305 | 0.010 |
Why?
|
| Amino Acids | 1 | 1992 | 728 | 0.010 |
Why?
|
| Contrast Media | 1 | 1996 | 1472 | 0.010 |
Why?
|
| Methylcholanthrene | 1 | 1988 | 29 | 0.010 |
Why?
|
| Cell Line | 2 | 1987 | 5114 | 0.000 |
Why?
|
| Organ Size | 1 | 1988 | 690 | 0.000 |
Why?
|
| Mitoguazone | 1 | 1986 | 9 | 0.000 |
Why?
|
| Hydroxyurea | 1 | 1987 | 204 | 0.000 |
Why?
|
| Cholangitis | 1 | 1986 | 48 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1986 | 192 | 0.000 |
Why?
|
| Urogenital Neoplasms | 1 | 1987 | 108 | 0.000 |
Why?
|
| Nucleosides | 1 | 1986 | 60 | 0.000 |
Why?
|
| Mannitol | 1 | 1985 | 54 | 0.000 |
Why?
|
| Diuresis | 1 | 1985 | 63 | 0.000 |
Why?
|
| Acenaphthenes | 1 | 1984 | 6 | 0.000 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1986 | 193 | 0.000 |
Why?
|
| Peptichemio | 1 | 1984 | 12 | 0.000 |
Why?
|
| Phlebitis | 1 | 1984 | 8 | 0.000 |
Why?
|
| Blood Coagulation | 1 | 1986 | 185 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1985 | 257 | 0.000 |
Why?
|
| Ribonucleotides | 1 | 1984 | 52 | 0.000 |
Why?
|
| Thiotepa | 1 | 1984 | 118 | 0.000 |
Why?
|
| Transforming Growth Factors | 1 | 1984 | 40 | 0.000 |
Why?
|
| Specimen Handling | 1 | 1985 | 299 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1986 | 482 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1984 | 388 | 0.000 |
Why?
|
| Hyperglycemia | 1 | 1984 | 333 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1984 | 731 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1985 | 691 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1984 | 3001 | 0.000 |
Why?
|
| Leukemia | 1 | 1984 | 1635 | 0.000 |
Why?
|